Amgad E. El-Agroudy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amgad E. El-Agroudy has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mohamed A. Ghoneim
Urology Department, Urology and Nephrology Center, Mansoura, Egypt
8 shared publications - Ahmed Abdulrahman Shokeir
Urology and Nephrology Center Mansoura University Mansoura Egypt
6 shared publications Amani M Ismail
Urology and Nephrology Centre, University of Mansoura, Mansoura, Egypt
4 shared publicationsMahmoud El-Baz
4 shared publicationsEhab W Wafa
3 shared publicationsKhaled Mahmoud
University of Mansoura
3 shared publications
Latest Publications
- Open Access
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 27 (1) , 28-36
Efficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study
We report a prospective, open-label, randomized study to evaluate the safety and efficacy of converting patients with a stable renal function from tacrolimus (Tac)-based regimen to a sirolimus (SRL)-based regimen after kidney transplantation. Fifty-eight low-risk renal allograft recipients who receiving Tac 6 months posttransplant, were randomly assigned to continue Tac (n = 29) or convert to SRL (n = 29). We evaluated the 3-year outcomes including patient and graft survival, graft function, and safety profile. Three-year patient and graft survival in SRL and Tac groups were 93.1% versus 100% (P = 0.32), and 89.7% versus 100% (P = 0.11), respectively. However, the SRL group had a significantly better renal function, from the 2nd year posttransplant until the last follow-up. Four (13.8%) patients in the SRL group and 3 (10.3%) in the Tac group (P = 0.5) developed biopsy-proven acute rejection. Mean urinary protein excretion increased significantly after SRL conversion. Diastolic blood pressure was significantly lower at the end of the study in patients who eliminated Tac (80.4 vs. 75.6 mmHg in Tac and SRL group, respectively) (P = 0.03). Mean hemoglobin concentrations decreased after SRL conversion and remained significantly lower from 12 months to 36 months (P = 0.01). The mean serum cholesterol (540 ± 44 mg/dl) and triglyceride (177 ± 27 mg/dl) increased significantly in the SRL group, compared to Tac group (487 ± 62 mg/dl) (P = 0.03) and (141 ± 26 mg/dl) (P = 0.04). Our experience demonstrates that conversion to SRL from calcineurin inhibitors-based therapy may result in better renal function and blood pressure control in renal transplant recipients without an increased risk of acute rejection. However, these benefits have not resulted in a growing advantage in graft or patient survival.
- 1 January 2017
- Published by Scientific Scholar in Indian Journal of Nephrology
- Vol. 27 (1) , 28-36
Open AccessEfficacy and safety of early tacrolimus conversion to sirolimus after kidney transplantation: Long-term results of a prospective randomized study
We report a prospective, open-label, randomized study to evaluate the safety and efficacy of converting patients with a stable renal function from tacrolimus (Tac)-based regimen to a sirolimus (SRL)-based regimen after kidney transplantation. Fifty-eight low-risk renal allograft recipients who receiving Tac 6 months posttransplant, were randomly assigned to continue Tac (n = 29) or convert to SRL (n = 29). We evaluated the 3-year outcomes including patient and graft survival, graft function, and safety profile. Three-year patient and graft survival in SRL and Tac groups were 93.1% versus 100% (P = 0.32), and 89.7% versus 100% (P = 0.11), respectively. However, the SRL group had a significantly better renal function, from the 2nd year posttransplant until the last follow-up. Four (13.8%) patients in the SRL group and 3 (10.3%) in the Tac group (P = 0.5) developed biopsy-proven acute rejection. Mean urinary protein excretion increased significantly after SRL conversion. Diastolic blood pressure was significantly lower at the end of the study in patients who eliminated Tac (80.4 vs. 75.6 mmHg in Tac and SRL group, respectively) (P = 0.03). Mean hemoglobin concentrations decreased after SRL conversion and remained significantly lower from 12 months to 36 months (P = 0.01). The mean serum cholesterol (540 ± 44 mg/dl) and triglyceride (177 ± 27 mg/dl) increased significantly in the SRL group, compared to Tac group (487 ± 62 mg/dl) (P = 0.03) and (141 ± 26 mg/dl) (P = 0.04). Our experience demonstrates that conversion to SRL from calcineurin inhibitors-based therapy may result in better renal function and blood pressure control in renal transplant recipients without an increased risk of acute rejection. However, these benefits have not resulted in a growing advantage in graft or patient survival.
- Open Access
- 6 August 2016
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 13 (3) , 16-22
Sirolimus-based, calcineurin inhibitor- free regimen in kidney transplant patients: An open-label, randomized, controlled trial
- 6 August 2016
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 13 (3) , 16-22
Open AccessSirolimus-based, calcineurin inhibitor- free regimen in kidney transplant patients: An open-label, randomized, controlled trial
- 27 September 2012
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 10 (5) , 458-465
Risk Factors and Outcomes of New-Onset Diabetes After Transplant: Single-Centre Experience
We sought to study the prevalence, risk factors, and long-term prognosis of posttransplant diabetes mellitus. We studied all patients with end-stage renal disease without diabetic nephropathy who received a kidney transplant and were followed-up at our center since 1983 (n=218; age, 44.3 ± 13.1 y). Patients with new-onset diabetes after transplant were compared to kidney transplant recipients without risk factors for diabetes mellitus. Patients with new-onset diabetes after transplant were divided into subgroups according to time of onset (early; < 90 d vs late, ≥ 90 d). In total, 73/218 patients (33%) developed new-onset diabetes after transplant. Patients with new-onset diabetes after transplant were significantly older (51.2 ± 11.4 vs 40.7 ± 12.5 y; P < .001) and had a tendency to have a higher body mass index (29.6 ± 8.7 vs 21.6 ± 7.8 kg/m2; P =.05) than those that did not have new-onset diabetes after transplant. In multivariate analysis, age (P < .001), hepatitis C virus infection (P < .05), family history of diabetes mellitus (P < .03), and tacrolimus use (P < .001) were independent risk factors. Five- and 10-year death censored patient survival rates were worse in those that had new-onset diabetes after transplant compared with controls (log rank, 0.04), whereas there was no difference in outcomes between the early and late subgroups. The prevalence of new-onset diabetes after transplant was 33%. Age, body weight at time of transplant, tacrolimus use, family history of diabetes mellitus, and hepatitis C virus infection are independent risk factors for new-onset diabetes after transplant. New-onset diabetes after transplant has a negative effect on patient survival, irrespective of the time of onset and duration of diabetes.
- 27 September 2012
- Published by Baskent University in Experimental and Clinical Transplantation
- Vol. 10 (5) , 458-465
Risk Factors and Outcomes of New-Onset Diabetes After Transplant: Single-Centre Experience
We sought to study the prevalence, risk factors, and long-term prognosis of posttransplant diabetes mellitus. We studied all patients with end-stage renal disease without diabetic nephropathy who received a kidney transplant and were followed-up at our center since 1983 (n=218; age, 44.3 ± 13.1 y). Patients with new-onset diabetes after transplant were compared to kidney transplant recipients without risk factors for diabetes mellitus. Patients with new-onset diabetes after transplant were divided into subgroups according to time of onset (early; < 90 d vs late, ≥ 90 d). In total, 73/218 patients (33%) developed new-onset diabetes after transplant. Patients with new-onset diabetes after transplant were significantly older (51.2 ± 11.4 vs 40.7 ± 12.5 y; P < .001) and had a tendency to have a higher body mass index (29.6 ± 8.7 vs 21.6 ± 7.8 kg/m2; P =.05) than those that did not have new-onset diabetes after transplant. In multivariate analysis, age (P < .001), hepatitis C virus infection (P < .05), family history of diabetes mellitus (P < .03), and tacrolimus use (P < .001) were independent risk factors. Five- and 10-year death censored patient survival rates were worse in those that had new-onset diabetes after transplant compared with controls (log rank, 0.04), whereas there was no difference in outcomes between the early and late subgroups. The prevalence of new-onset diabetes after transplant was 33%. Age, body weight at time of transplant, tacrolimus use, family history of diabetes mellitus, and hepatitis C virus infection are independent risk factors for new-onset diabetes after transplant. New-onset diabetes after transplant has a negative effect on patient survival, irrespective of the time of onset and duration of diabetes.
- 26 January 2010
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 14 (2) , 152-157
Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients
Inflammation has been associated with atherosclerotic cardiovascular disease (CVD) and anemia in patients with end-stage renal disease (ESRD) which may lead to left ventricular impairment via myocardial hypertrophy and/or ischemia. We therefore sought to investigate serum levels of sFas in uremic patients and its correlation with known markers of inflammation and CVD. The study included 30 patients on hemodialysis, 30 patients with chronic kidney disease (CKD), and 30 normal control subjects. We measured serum levels of sFas, C-reactive protein (CRP), and albumin. We also investigated the association of serum sFas levels with the presence of CVD by echocardiographic assessment before and after 1 year. Levels of sFas were elevated in CKD and ESRD patients compared to controls. sFas levels correlated positively with serum creatinine and negatively with serum albumin. In the dialysis patients, we observed that sFas levels were higher among those with CVD. Compared with baseline, after 1 year of follow-up there was a significant decrease in left ventricular (LV) ejection fraction, increases in LV end-diastolic dimension and LV end-systolic dimension, and myocardial ischemic changes. These results suggest that sFas may be a marker of inflammation in CKD and ESRD patients.
- 26 January 2010
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 14 (2) , 152-157
Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients
Inflammation has been associated with atherosclerotic cardiovascular disease (CVD) and anemia in patients with end-stage renal disease (ESRD) which may lead to left ventricular impairment via myocardial hypertrophy and/or ischemia. We therefore sought to investigate serum levels of sFas in uremic patients and its correlation with known markers of inflammation and CVD. The study included 30 patients on hemodialysis, 30 patients with chronic kidney disease (CKD), and 30 normal control subjects. We measured serum levels of sFas, C-reactive protein (CRP), and albumin. We also investigated the association of serum sFas levels with the presence of CVD by echocardiographic assessment before and after 1 year. Levels of sFas were elevated in CKD and ESRD patients compared to controls. sFas levels correlated positively with serum creatinine and negatively with serum albumin. In the dialysis patients, we observed that sFas levels were higher among those with CVD. Compared with baseline, after 1 year of follow-up there was a significant decrease in left ventricular (LV) ejection fraction, increases in LV end-diastolic dimension and LV end-systolic dimension, and myocardial ischemic changes. These results suggest that sFas may be a marker of inflammation in CKD and ESRD patients.
- 1 December 2009
- Vol. 7 (4) , 228-32
Characteristics of patients with Banff borderline changes in renal allograft biopsies.
The aim of this retrospective study was to characterize the patients who experienced borderline rejection. Patients with a minimum follow-up of 2 years were enrolled in this study. Forty-seven patients out of 106 patients with borderline rejection (after exclusion of those with associated chronic interstitial fibrosis) were compared with patients with acute cellular rejection grade 1 (n = 650), and patients free of rejection episodes (n = 444) regarding the different characteristics. Patients aged 20 years or younger were frequently in borderline rejection group than other groups (which was statistically significant) (P = .001). Significant differences were found in recipient and donor ages, consanguinity, pretransplant blood transfusion, and immunosuppression plan. Most patients in borderline rejection group received triple immunosuppression therapy than other groups (P = .001). Univariate and multivariate regression analysis of different variables on graft survival in borderline rejection patients revealed that none of them was statistically significant. Borderline rejection is a frequent finding in biopsy-proven acute rejection after kidney transplant. Time of occurrence, frequency, treatment or not, and response to therapy were not predictors to graft survival.
- 1 December 2009
- Vol. 7 (4) , 228-32
Characteristics of patients with Banff borderline changes in renal allograft biopsies.
The aim of this retrospective study was to characterize the patients who experienced borderline rejection. Patients with a minimum follow-up of 2 years were enrolled in this study. Forty-seven patients out of 106 patients with borderline rejection (after exclusion of those with associated chronic interstitial fibrosis) were compared with patients with acute cellular rejection grade 1 (n = 650), and patients free of rejection episodes (n = 444) regarding the different characteristics. Patients aged 20 years or younger were frequently in borderline rejection group than other groups (which was statistically significant) (P = .001). Significant differences were found in recipient and donor ages, consanguinity, pretransplant blood transfusion, and immunosuppression plan. Most patients in borderline rejection group received triple immunosuppression therapy than other groups (P = .001). Univariate and multivariate regression analysis of different variables on graft survival in borderline rejection patients revealed that none of them was statistically significant. Borderline rejection is a frequent finding in biopsy-proven acute rejection after kidney transplant. Time of occurrence, frequency, treatment or not, and response to therapy were not predictors to graft survival.
- 3 June 2009
- Vol. 14 (2) , 13-9
The health of elderly living kidney donors after donation.
Elderly donors may have increased risks in the peri- and post-transplant period. We performed a retrospective study to determine the outcome of elderly living donors in our center. Analysis of our live-related transplant program from Mar 1976 to Mar 2005 revealed that 146 donors were older than 50 years (range 50 to 69 yr) at the time of transplantation. We attempted to contact all donors to determine long-term outcome regarding their remaining kidney but 78 (53.4%) of them responded and were subjected to assessment. Their data were compared to the age matched health tables of the Egyptian general populations. Most donors (85%) gave their kidneys to their offspring. Twenty four donors became hypertensive (30.8%) and nearly 62% received one drug only. Five donors were diabetics and 5 with arrhythmia. The mean serum creatinine at the follow up was 1.0+/-0.9 mg/dl. Five donors developed proteinuria, none of them with >2 gm/day. The rate of diabetes and hypertension was similar to the age matched general population. Donor nephrectomy has minimal adverse effects on overall health status. Our data underscore the need to develop prospective trials for long-term follow up of elderly kidney donors.
- 3 June 2009
- Vol. 14 (2) , 13-9
The health of elderly living kidney donors after donation.
Elderly donors may have increased risks in the peri- and post-transplant period. We performed a retrospective study to determine the outcome of elderly living donors in our center. Analysis of our live-related transplant program from Mar 1976 to Mar 2005 revealed that 146 donors were older than 50 years (range 50 to 69 yr) at the time of transplantation. We attempted to contact all donors to determine long-term outcome regarding their remaining kidney but 78 (53.4%) of them responded and were subjected to assessment. Their data were compared to the age matched health tables of the Egyptian general populations. Most donors (85%) gave their kidneys to their offspring. Twenty four donors became hypertensive (30.8%) and nearly 62% received one drug only. Five donors were diabetics and 5 with arrhythmia. The mean serum creatinine at the follow up was 1.0+/-0.9 mg/dl. Five donors developed proteinuria, none of them with >2 gm/day. The rate of diabetes and hypertension was similar to the age matched general population. Donor nephrectomy has minimal adverse effects on overall health status. Our data underscore the need to develop prospective trials for long-term follow up of elderly kidney donors.
- 1 April 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (2) , 156-160
Cyclosporine therapeutic monitoring with CMAX in kidney transplant recipients: racial considerations
The aim of the study was to assess whether the C2 level is a good parameter to predict a drug’s maximal concentration CMAX values in Egyptian kidney transplant recipients (KTR). Fifty stable kidney transplant recipients (KTR) with a previously confirmed diagnosis of schistosomal infection compared to KTR (n = 50) without schistosomal infection regarding CsA concentrations at time 0 (trough), 1.5, 2, 2.5, 3, and 3.5 h post-CsA. Statistical significance of linear regression between different CsA time concentrations and drug dosages was calculated. Patients in schistosomal group, had significantly lower C2 levels (511 ± 118 ng/ml) compared with control group (669 ± 213 ng/ml) (P < 0.05), whereas C2.5 level was significantly higher (730 ± 215 and 527 ± 129 ng/ml, respectively; P < 0.05). Only C2.5 in schistosomal group had a significant linear regression relationship with both morning cyclosporine (CsA) dose and CsA dose expressed as mg/kg/day (P = 0.0123, r = 0.573018). Egyptian patients have special characteristics in drug absorption and metabolism, mostly due to schistosomal infection, and they may need the use of C2.5 for monitoring of CsA. If confirmed by subsequent larger experience, these findings may have a significant impact on our management of CyA immunosuppression in clinical renal transplantation in certain ethnicities.
- 1 April 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (2) , 156-160
Cyclosporine therapeutic monitoring with CMAX in kidney transplant recipients: racial considerations
The aim of the study was to assess whether the C2 level is a good parameter to predict a drug’s maximal concentration CMAX values in Egyptian kidney transplant recipients (KTR). Fifty stable kidney transplant recipients (KTR) with a previously confirmed diagnosis of schistosomal infection compared to KTR (n = 50) without schistosomal infection regarding CsA concentrations at time 0 (trough), 1.5, 2, 2.5, 3, and 3.5 h post-CsA. Statistical significance of linear regression between different CsA time concentrations and drug dosages was calculated. Patients in schistosomal group, had significantly lower C2 levels (511 ± 118 ng/ml) compared with control group (669 ± 213 ng/ml) (P < 0.05), whereas C2.5 level was significantly higher (730 ± 215 and 527 ± 129 ng/ml, respectively; P < 0.05). Only C2.5 in schistosomal group had a significant linear regression relationship with both morning cyclosporine (CsA) dose and CsA dose expressed as mg/kg/day (P = 0.0123, r = 0.573018). Egyptian patients have special characteristics in drug absorption and metabolism, mostly due to schistosomal infection, and they may need the use of C2.5 for monitoring of CsA. If confirmed by subsequent larger experience, these findings may have a significant impact on our management of CyA immunosuppression in clinical renal transplantation in certain ethnicities.
- 1 March 2009
- Published by Wiley in Nephrology
- Vol. 14 (2) , 255-261
Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression
Mycophenolate mofetil (MMF) is a powerful immunosuppressive drug with established efficacy and safety. The long-term use of MMF may bring increased risk of for infection and malignancy and also increased cost of transplantation. The search for minimization of immunosuppressive protocol has led to an open randomized clinical trial of conversion from MMF to azathioprine (AZA). A total of 50 kidney allograft recipients treated with prednisone, sirolimus and MMF were randomized into two groups: converted (AZA group) and continuing (MMF group). The average duration of MMF therapy prior to conversion was 43 months in each group. Inclusion criteria included: patients with serum creatinine levels of less than 200 micromol/L; no past history of acute vascular rejection or recent acute rejection 6 months before randomization; and normal liver function tests. Baseline demographics were similar in the two groups. During the 12 month observation period, there were no acute rejection episodes in either group. There were no significant differences in overall patient or graft survival or function. AZA-treated patients had a lower incidence of gastrointestinal complications (P=0.03). Daily cost reduction in the AZA group was more than $US8.79/day per patient. In general, replacing MMF with AZA in stable renal transplant recipients is well tolerated and was cost effective with no increased risk of rejection. As the this study was on relatively small samples, larger and longer follow-up studies will be needed to confirm these expected advantages for the long-term outcome and to assess the long-term safety of this minimization of immunosuppressive therapy.
- 1 March 2009
- Published by Wiley in Nephrology
- Vol. 14 (2) , 255-261
Safe conversion of mycophenolate mofetil to azathioprine in kidney transplant recipients with sirolimus-based immunosuppression
Mycophenolate mofetil (MMF) is a powerful immunosuppressive drug with established efficacy and safety. The long-term use of MMF may bring increased risk of for infection and malignancy and also increased cost of transplantation. The search for minimization of immunosuppressive protocol has led to an open randomized clinical trial of conversion from MMF to azathioprine (AZA). A total of 50 kidney allograft recipients treated with prednisone, sirolimus and MMF were randomized into two groups: converted (AZA group) and continuing (MMF group). The average duration of MMF therapy prior to conversion was 43 months in each group. Inclusion criteria included: patients with serum creatinine levels of less than 200 micromol/L; no past history of acute vascular rejection or recent acute rejection 6 months before randomization; and normal liver function tests. Baseline demographics were similar in the two groups. During the 12 month observation period, there were no acute rejection episodes in either group. There were no significant differences in overall patient or graft survival or function. AZA-treated patients had a lower incidence of gastrointestinal complications (P=0.03). Daily cost reduction in the AZA group was more than $US8.79/day per patient. In general, replacing MMF with AZA in stable renal transplant recipients is well tolerated and was cost effective with no increased risk of rejection. As the this study was on relatively small samples, larger and longer follow-up studies will be needed to confirm these expected advantages for the long-term outcome and to assess the long-term safety of this minimization of immunosuppressive therapy.
- 1 February 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (1) , 66-72
Long-term graft outcome in patients with chronic allograft nephropathy after immunosuppression modifications
This retrospective study was conducted to assess the efficacy and safety of immunosuppression conversion on progression of chronic allograft nephropathy (CAN). One-hundred and seventy-four cyclosporin (CsA)-treated renal transplant recipients were studied. Patients were included if they had a biopsy-proven CAN (mild to moderate) with serum creatinine ≤3.5 mg/dL. Patient treatment was switched to either: (A) MMF/reduced dose CsA (MMF for azathioprine (Aza); n = 132); or (B) Aza/Tac for CsA (n = 42). Patient records were checked for graft function and survival, and for co-morbidities after conversion. Mean follow-up before conversion was 52.2 ± 31.1 and 47.9 ± 27.4 months for groups A and B, respectively. There was significant deterioration of graft function in group B after five years (P < 0.5). Ten-year actuarial graft survival was 38% in group A and 19% in group B (P = 0.04). Nine patients (five patients and four patients in groups A and B, respectively) started dialysis within 12 months. Tacrolimus-treated patients had a lower insignificant incidence of hyperlipidemia (P = 0.05), but a significantly higher incidence of diabetes mellitus (P = 0.04).There was no significant change or difference in blood pressure between groups. Our results suggest that in patients with CAN and deteriorating allograft function, CsA minimization and addition of MMF achieved favorable efficacies in retarding the decline of graft function. Further prospective studies with larger cohorts are needed for validation.
- 1 February 2009
- Published by Springer Nature in Clinical and Experimental Nephrology
- Vol. 13 (1) , 66-72
Long-term graft outcome in patients with chronic allograft nephropathy after immunosuppression modifications
This retrospective study was conducted to assess the efficacy and safety of immunosuppression conversion on progression of chronic allograft nephropathy (CAN). One-hundred and seventy-four cyclosporin (CsA)-treated renal transplant recipients were studied. Patients were included if they had a biopsy-proven CAN (mild to moderate) with serum creatinine ≤3.5 mg/dL. Patient treatment was switched to either: (A) MMF/reduced dose CsA (MMF for azathioprine (Aza); n = 132); or (B) Aza/Tac for CsA (n = 42). Patient records were checked for graft function and survival, and for co-morbidities after conversion. Mean follow-up before conversion was 52.2 ± 31.1 and 47.9 ± 27.4 months for groups A and B, respectively. There was significant deterioration of graft function in group B after five years (P < 0.5). Ten-year actuarial graft survival was 38% in group A and 19% in group B (P = 0.04). Nine patients (five patients and four patients in groups A and B, respectively) started dialysis within 12 months. Tacrolimus-treated patients had a lower insignificant incidence of hyperlipidemia (P = 0.05), but a significantly higher incidence of diabetes mellitus (P = 0.04).There was no significant change or difference in blood pressure between groups. Our results suggest that in patients with CAN and deteriorating allograft function, CsA minimization and addition of MMF achieved favorable efficacies in retarding the decline of graft function. Further prospective studies with larger cohorts are needed for validation.
- 1 December 2008
- Vol. 6 (4) , 282-6
Cyclosporine therapeutic monitoring with Cmax in kidney transplant recipients: does it fit for all populations?
We sought to assess whether the single cyclosporine concentration taken 2 hours after administration (C2) is a good parameter to predict a drug's maximal concentration (Cmax) value in Egyptian kidney transplant recipients. Fifty stable Egyptian kidney transplant recipients with a previously diagnosed schistosomal infection were compared with 50 Egyptian kidney transplant recipients without a schistosomal infection regarding cyclosporine concentrations at time 0 (trough), and then at 1.5, 2, 2.5, 3, and 3.5 hours after a dose of cyclosporine. We used a linear regression analysis to assess any statistically significant differences between the different cyclosporine time concentrations and drug dosages. Patients in the schistosomal group had significantly lower C2 levels (511 -/+ 118 nmol/L) compared with those in the nonschistosomal (control) group (669 -/+ 213 nmol/L) (P < .05), whereas the C2.5 level was significantly higher (730 -/+ 215 and 527 -/+ 129 nmol/L, respectively; P < .05). A significant linear regression relation was determined for only C2.5 in the schistosomal group with both morning cyclosporine dose and cyclosporine dose expressed as mg/kg/d (P = .0123, r = .573018). Egyptian patients have special characteristics with regard to drug absorption and metabolism, mostly owing to schistosomal infection, and they may need the use of C2.5 to monitor cyclosporine. If confirmed by subsequent, larger studies, our findings may have a significant effect on our understanding and management of cyclosporine immunosuppression in clinical renal transplants with persons of different ethnicities.
- 1 December 2008
- Vol. 6 (4) , 282-6
Cyclosporine therapeutic monitoring with Cmax in kidney transplant recipients: does it fit for all populations?
We sought to assess whether the single cyclosporine concentration taken 2 hours after administration (C2) is a good parameter to predict a drug's maximal concentration (Cmax) value in Egyptian kidney transplant recipients. Fifty stable Egyptian kidney transplant recipients with a previously diagnosed schistosomal infection were compared with 50 Egyptian kidney transplant recipients without a schistosomal infection regarding cyclosporine concentrations at time 0 (trough), and then at 1.5, 2, 2.5, 3, and 3.5 hours after a dose of cyclosporine. We used a linear regression analysis to assess any statistically significant differences between the different cyclosporine time concentrations and drug dosages. Patients in the schistosomal group had significantly lower C2 levels (511 -/+ 118 nmol/L) compared with those in the nonschistosomal (control) group (669 -/+ 213 nmol/L) (P < .05), whereas the C2.5 level was significantly higher (730 -/+ 215 and 527 -/+ 129 nmol/L, respectively; P < .05). A significant linear regression relation was determined for only C2.5 in the schistosomal group with both morning cyclosporine dose and cyclosporine dose expressed as mg/kg/d (P = .0123, r = .573018). Egyptian patients have special characteristics with regard to drug absorption and metabolism, mostly owing to schistosomal infection, and they may need the use of C2.5 to monitor cyclosporine. If confirmed by subsequent, larger studies, our findings may have a significant effect on our understanding and management of cyclosporine immunosuppression in clinical renal transplants with persons of different ethnicities.